Should I buy or sell Accuray stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAY shares. View ARAY analyst ratings or view top-rated stocks .

What is Accuray's stock price target for 2024?

3 brokers have issued 1-year target prices for Accuray's shares. Their ARAY share price targets range from $7.50 to $9.00. On average, they anticipate the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 276.7% from the stock's current price. View analysts price targets for ARAY or view top-rated stocks among Wall Street analysts .

How have ARAY shares performed in 2024?

Accuray's stock was trading at $2.83 at the start of the year. Since then, ARAY stock has decreased by 22.6% and is now trading at $2.19. View the best growth stocks for 2024 here .

When is Accuray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our ARAY earnings forecast .

How were Accuray's earnings last quarter?

Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Wednesday, January, 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The medical equipment provider earned $107.24 million during the quarter, compared to analyst estimates of $107.11 million. Accuray had a negative net margin of 3.25% and a negative trailing twelve-month return on equity of 28.11%. During the same period in the prior year, the business earned ($0.02) EPS.

What guidance has Accuray issued on next quarter's earnings?

Accuray updated its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $460.0 million-$470.0 million, compared to the consensus revenue estimate of $463.0 million.

What is Joshua Levine's approval rating as Accuray's CEO?

107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com . Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.

What other stocks do shareholders of Accuray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD) , NVIDIA (NVDA) , Intel (INTC) , Activision Blizzard (ATVI) , Geron (GERN) , Sorrento Therapeutics (SRNE) , Tesla (TSLA) , AbbVie (ABBV) , QUALCOMM (QCOM) and ADMA Biologics (ADMA) .

Who are Accuray's major shareholders?

Accuray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.42%) and Bridge City Capital LLC (0.12%). Insiders that own company stock include Ali Pervaiz, Brandon W Green , Byron C Scott , Gina Corradetti, Jesse Chew , Joseph E Whitters , Joshua Levine , Michael Hoge , Patrick Spine , Sandeep Chalke and Suzanne C Winter . View institutional ownership trends .

How do I buy shares of Accuray?

Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Accuray have any subsidiaries?

The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated. Read More

NASDAQ:ARAY

Accuray (ARAY) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free ARAY Stock Alerts

$2.19

-0.04 (-1.79%)

(As of 04/17/2024 ET)

Compare

Today's Range: $2.17
▼
$2.25
50-Day Range: $2.19
▼
$2.90
52-Week Range: $2.17
▼
$4.30

Volume: 464,383 shs
Average Volume: 435,975 shs
Market Capitalization: $217.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.25

Get Accuray alerts:

Accuray MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 276.7% Upside
$8.25 Price Target
Short Interest: Bearish
5.31% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.77
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.07) to $0.14 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

324th out of 913 stocks

Surgical & Medical Instruments Industry

34th out of 89 stocks

3.5

Analyst's Opinion

Consensus Rating
Accuray has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Accuray has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
5.31% of the outstanding shares of Accuray have been sold short.
Short Interest Ratio / Days to Cover
Accuray has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Accuray has recently decreased by 2.77%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Accuray does not currently pay a dividend.
Dividend Growth
Accuray does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accuray has received a 72.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Radiation therapy machines", "Radiation therapy software", and "Installation services of radiation therapy machines" products. See details.
Environmental Sustainability
The Environmental Impact score for Accuray is -0.77.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Accuray this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 2 people have added Accuray to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accuray insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.78% of the stock of Accuray is held by insiders.
Percentage Held by Institutions
64.08% of the stock of Accuray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accuray are expected to grow in the coming year, from ($0.07) to $0.14 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accuray is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accuray is -14.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Accuray has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Timothy Sykes

Urgent alert: open this for a huge profit potential

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

About Accuray Stock (NASDAQ:ARAY)

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy System, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.

ARAY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ARAY Stock News Headlines

April 17, 2024 | finance.yahoo.com

Accuray to Report Third Quarter Fiscal 2024 Financial Results on May 1, 2024

April 8, 2024 | finance.yahoo.com

Accuray (NASDAQ:ARAY) shareholders have endured a 54% loss from investing in the stock three years ago

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 7, 2024 | seekingalpha.com

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

March 29, 2024 | finance.yahoo.com

On National Doctors' Day, MDVIP to Deliver Thousands of Patient Stories Celebrating Their Primary Care Physicians

March 29, 2024 | finance.yahoo.com

Functional Food Market Size is projected to reach USD 347231 million by 2031, growing at a CAGR of 6.84%: Straits Research

March 27, 2024 | markets.businessinsider.com

Accuray Reports Positive Results For CyberKnife System In High-risk, Recurrent Prostate Cancer

March 26, 2024 | prnewswire.com

New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can be Effectively Treated in 5 Days Using the Accuray CyberKnife® System

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 16, 2024 | finance.yahoo.com

ARAY Apr 2024 4.000 call

March 4, 2024 | prnewswire.com

Accuray Incorporated to Speak at 36th Annual Roth Conference

February 27, 2024 | prnewswire.com

Accuray Incorporated to Speak at Oppenheimer 34th Annual Healthcare MedTech & Services Conference

February 22, 2024 | finance.yahoo.com

Accuray Incorporated (NASDAQ:ARAY) is largely controlled by institutional shareholders who own 59% of the company

February 21, 2024 | investorplace.com

7 Screaming Stock Buys for Under $5

February 17, 2024 | finance.yahoo.com

ARAY Mar 2024 2.000 call

February 17, 2024 | finance.yahoo.com

ARAY Mar 2024 2.000 put

February 13, 2024 | msn.com

Roth MKM starts Accuray at buy, cites expansion into emerging markets

February 13, 2024 | markets.businessinsider.com

Accuray’s Growth Prospects Bolstered by Strategic Market Expansion and Innovation, Recommends Buy

February 13, 2024 | finance.yahoo.com

Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System

February 2, 2024 | finance.yahoo.com

Accuray Second Quarter 2024 Earnings: EPS Misses Expectations

February 1, 2024 | finance.yahoo.com

Accuray Incorporated (NASDAQ:ARAY) Q2 2024 Earnings Call Transcript

February 1, 2024 | markets.businessinsider.com

Accuray Buy Rating Affirmed on Strong Growth and Solid Financials Despite Headwinds

February 1, 2024 | finance.yahoo.com

Accuray Inc (ARAY) Reports Fiscal Q2 2024 Results: Order Growth and Service Revenue Expansion ...

February 1, 2024 | finanznachrichten.de

Accuray Incorporated: Accuray Reports Fiscal 2024 Second Quarter Financial Results

February 1, 2024 | msn.com

Accuray Incorporated Analysts and Investors Presentation Update

February 1, 2024 | finance.yahoo.com

Q2 2024 Accuray Inc Earnings Call

January 31, 2024 | benzinga.com

Recap: Accuray Q2 Earnings

See More Headlines

Receive ARAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accuray and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/31/2024
Today: 4/17/2024
Next Earnings (Estimated): 4/24/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:ARAY
CUSIP: 00439710
CIK: 1138723
Web: www.accuray.com
Phone: (408) 716-4600
Fax: 408-716-4601
Employees: 1,024
Year Founded: 1990

Price Target and Rating

Average Stock Price Target: $8.25
High Stock Price Target: $9.00
Low Stock Price Target: $7.50
Potential Upside/Downside: +278.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,280,000.00
Net Margins: -3.25%
Pretax Margin: -2.38%
Return on Equity: -28.11%
Return on Assets: -3.05%

Debt

Debt-to-Equity Ratio: 3.53
Current Ratio: 1.58
Quick Ratio: 0.84

Sales & Book Value

Annual Sales: $447.61 million
Price / Sales: 0.48
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.56 per share
Price / Book: 3.89

Miscellaneous

Outstanding Shares: 99,170,000
Free Float: 95,420,000
Market Cap: $216.19 million
Optionable: Optionable
Beta: 1.44

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Ms. Suzanne Winter M.B.A. (Age 61)
President, CEO & Director
Comp: $1.02M
Mr. Ali Pervaiz (Age 44)
Senior VP & CFO
Comp: $601.12k
Mr. Michael Hoge (Age 57)
Senior Vice President of Global Operations
Comp: $540.12k
Mr. Jesse Chew (Age 43)
Senior VP, Chief Legal Officer & Company Secretary
Comp: $621.2k
Mr. Sandeep Chalke (Age 58)
Senior VP & Chief Commercial Officer
Comp: $826.18k
Ms. Gina Corradetti (Age 50)
VP, Chief Accounting Officer, Principal Accounting Officer & Controller
Mr. John M. Dunn
Vice President, Chief Information & Security Officer
Beth Kaplan
Public Relations Director
Ms. Melanie Gebauer
Vice President of Global Human Resources
Mr. Juki Hozumi
President & GM of Japan Region

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARAY Stock Analysis - Frequently Asked Questions

Should I buy or sell Accuray stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARAY shares.
View ARAY analyst ratings or view top-rated stocks.
What is Accuray's stock price target for 2024?: 3 brokers have issued 1-year target prices for Accuray's shares. Their ARAY share price targets range from $7.50 to $9.00. On average, they anticipate the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 276.7% from the stock's current price.
View analysts price targets for ARAY or view top-rated stocks among Wall Street analysts.
How have ARAY shares performed in 2024?: Accuray's stock was trading at $2.83 at the start of the year. Since then, ARAY stock has decreased by 22.6% and is now trading at $2.19.
View the best growth stocks for 2024 here.
When is Accuray's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ARAY earnings forecast.
How were Accuray's earnings last quarter?: Accuray Incorporated (NASDAQ:ARAY) issued its quarterly earnings data on Wednesday, January, 31st. The medical equipment provider reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.05. The medical equipment provider earned $107.24 million during the quarter, compared to analyst estimates of $107.11 million. Accuray had a negative net margin of 3.25% and a negative trailing twelve-month return on equity of 28.11%. During the same period in the prior year, the business earned ($0.02) EPS.
What guidance has Accuray issued on next quarter's earnings?: Accuray updated its FY 2024 earnings guidance on Wednesday, January, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $460.0 million-$470.0 million, compared to the consensus revenue estimate of $463.0 million.

What is Joshua Levine's approval rating as Accuray's CEO?: 107 employees have rated Accuray Chief Executive Officer Joshua Levine on Glassdoor.com. Joshua Levine has an approval rating of 45% among the company's employees. This puts Joshua Levine in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 75.0% of employees surveyed would recommend working at Accuray to a friend.
What other stocks do shareholders of Accuray own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Intel (INTC), Activision Blizzard (ATVI), Geron (GERN), Sorrento Therapeutics (SRNE), Tesla (TSLA), AbbVie (ABBV), QUALCOMM (QCOM) and ADMA Biologics (ADMA).
Who are Accuray's major shareholders?: Accuray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverberg Bernstein Capital Management LLC (0.42%) and Bridge City Capital LLC (0.12%). Insiders that own company stock include Ali Pervaiz, Brandon W Green, Byron C Scott, Gina Corradetti, Jesse Chew, Joseph E Whitters, Joshua Levine, Michael Hoge, Patrick Spine, Sandeep Chalke and Suzanne C Winter.
View institutional ownership trends.
How do I buy shares of Accuray?: Shares of ARAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Accuray have any subsidiaries?: The following companies are subsidiares of Accuray: Accuray Accelerator Technology (Chengdu) Company Limited, Accuray Asia Ltd., Accuray Belgium BVBA, Accuray Brasil Comércio, Accuray Cayman Islands, Accuray Europe SAS, Accuray International SARL, Accuray Italy S.R.L, Accuray Japan K.K., Accuray Medical Equipment (Canada) Ltd., Accuray Medical Equipment (India) Private Limited, Accuray Medical Equipment (Rus) LLC., Accuray Medical Equipment (Shanghai) Co. Ltd., Accuray Medical Equipment GmbH, Accuray Mexico S.A. de C.V., Accuray Netherlands B.V., Accuray Spain S.L.U., Accuray UK Ltd., Morphormics Inc., and TomoTherapy Incorporated.
Read More

This page (NASDAQ:ARAY) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Accuray (ARAY) Stock Price, News & Analysis

Accuray MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Accuray Stock (NASDAQ:ARAY)

ARAY Stock Price History

ARAY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ARAY Stock Analysis - Frequently Asked Questions

Overall MarketRank^™